This ASX small-cap stock just jumped 10%. Here's why

This ASX small-cap stock surged after the company posted a strong quarterly and half-year sales update.

| More on:
Two lab workers fist pump each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Biome Australia reported a 40.9% increase in Q2 FY26 revenue and a record $6.48 million in sales despite a typically slow December quarter.
  • The company's sales for the first half of FY26 reached $12.42 million, marking a 40.2% growth year over year, driven by strong demand for its clinically-backed probiotics.
  • With significant revenue growth in a defensive healthcare sector, investors are reassessing Biome's rapid growth trajectory amid challenging economic conditions.

The Biome Australia Ltd (ASX: BIO) share price is in the spotlight on Monday. This comes after the company released a strong sales update to the market.

At the time of writing, the Biome share price is up 10.84% to 46 cents, making it one of the stronger performers on the ASX today.

By comparison, the broader S&P/ASX All Ords Index (ASX: XAO) is currently flat.

So, what did Biome report, and what else could be driving the share price higher?

Sales keep growing despite a tough quarter

According to the release, Biome reported Q2 FY26 revenue of $6.48 million. That result represents 40.9% growth compared to the same quarter last year and 9.1% growth compared to the previous quarter.

This is a strong result because the December quarter is usually a slower time for the business. There are fewer trading days, and pharmacies often focus more on gift items than health products.

Even with those challenges, Biome still delivered its strongest second-quarter result on record. This shows demand for its probiotic products remains strong.

A solid first half of the year

Looking beyond the quarter, Biome also shared its half-year results for FY26.

Total sales for the first half came in at $12.42 million, which is 40.2% higher than the same period last year. This compares with $8.86 million in the first half of FY25.

Management said the result reflects continued demand for its Activated Probiotics products. These products are backed by clinical research and are mainly sold through healthcare practitioners and pharmacies.

Why investors are paying attention

There are a few reasons why the market has responded positively today.

First, revenue growth above 40% is impressive for a consumer healthcare company. Second, achieving that growth during a seasonally slower period makes the result even more encouraging.

Biome also operates in the healthcare sector, which many investors see as more defensive. Demand for health products often holds up better when economic conditions are uncertain.

With a market capitalisation of around $102 million, investors may be starting to reassess how fast Biome can grow if current trends continue.

What to watch next

While today's update focused on sales, profitability will be the next area of interest for investors. The market will now start looking for signs that growth is translating into improving earnings.

But so far, Biome appears to have started FY26 well.

The next few months should give a clearer picture of whether that growth can continue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Small Cap Shares

three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
Small Cap Shares

Why 2025 was the year of the ASX small-cap shares

The ASX All Ords Index returned 10.56% while the ASX Small Ords Index produced 24.96%.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Small Cap Shares

This exciting small cap ASX share just delivered its 7th consecutive record quarter

Let's see why the market is bidding this stock higher today.

Read more »

Small business family created to include people with disabilities in order to have equal opportunity as everyone else.
Small Cap Shares

Morgans names 2 small cap ASX stocks to watch

Big things could be on the cards for buyers of these small caps according to the broker.

Read more »

Happy couple enjoying ice cream in retirement.
Small Cap Shares

Top broker just initiated coverage on two ASX small-cap stocks with a buy recommendation

Why these small-cap stocks are a buy according to Bell Potter.

Read more »

Two kids playing with wooden blocks, symbolising small cap shares and short selling.
Small Cap Shares

Why Australian small-cap shares are shining

Why are investors pushing their chips in on small caps?

Read more »

Happy healthcare workers in a labs
Small Cap Shares

The ASX small-cap stock that could double in value in 2026

Here's why Bell Potter thinks this small-cap stock is a buy.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Small Cap Shares

Why I think this ASX small-cap stock is a bargain at $4.26

I think this undervalued stock is going places.

Read more »

A man has a surprised and relieved expression on his face.
Small Cap Shares

Broker says this small cap ASX stock can rise ~90% following 'impressive deal'

Big things could be on the cards for this small cap according to Bell Potter.

Read more »